Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL (pages 355–364)
Rekha Raghunathan, Swetha Mahesula, Kranthi Kancharla, Preethi Janardhanan, Yeshwant L. A. Jadhav, Robert Nadeau, German P. Villa, Robert L. Cook, Colleen M. Witt, Jonathan A. L. Gelfond, Thomas G. Forsthuber and William E. Haskins
Article first published online: 27 FEB 2013 | DOI: 10.1002/ppsc.201200125
B-precursor acute lymphoblastic leukemia (B-ALL) lymphoblast (blast) internalization of anti-cytokine receptor-like factor 2 (CRLF2) antibody-armored biodegradable nanoparticles (AbBNPs) are investigated. Precise engineering of AbBNPs by size and Ab/BNP ratio may improve the internalization and selectivity of biodegradable nanoparticles for the treatment of leukemia.